Advanced Therapy Medicinal Products Market (By Therapy Type: Cell Therapy, CAR-T Therapy, Gene Therapy, Tissue Engineered Product) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Advanced Therapy Medicinal Products Market, Therapy Type

7.1.  Advanced Therapy Medicinal Products Market, Therapy Type, 2020-2030

7.1.1.    Cell Therapy

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    CAR-T Therapy

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Gene Therapy

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Tissue Engineered Product

7.1.4.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Advanced Therapy Medicinal Products Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, Therapy Type (2016-2030)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, Therapy Type (2016-2030)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, Therapy Type (2016-2030)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, Therapy Type (2016-2030)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, Therapy Type (2016-2030)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, Therapy Type (2016-2030)

Chapter 9.    Company Profiles

9.1.  Spark Therapeutics, Inc.

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Bluebird Bio, Inc.

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  Novartis AG

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  UniQure N.V.

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

9.5.  Celgene Corporation

9.5.1.    Company Overview

9.5.2.    Product Offerings

9.5.3.    Financial Performance

9.5.4.    Recent Initiatives

9.6.  Gilead Lifesciences, Inc.

9.6.1.    Company Overview

9.6.2.    Product Offerings

9.6.3.    Financial Performance

9.6.4.    Recent Initiatives

9.7.  Kolon TissueGene, Inc.

9.7.1.    Company Overview

9.7.2.    Product Offerings

9.7.3.    Financial Performance

9.7.4.    Recent Initiatives

9.8.  JCR Pharmaceuticals Co., Ltd.

9.8.1.    Company Overview

9.8.2.    Product Offerings

9.8.3.    Financial Performance

9.8.4.    Recent Initiatives

9.9.  MEDIPOST

9.9.1.    Company Overview

9.9.2.    Product Offerings

9.9.3.    Financial Performance

9.9.4.    Recent Initiatives

9.10.              Vericel Corporation

9.10.1.  Company Overview

9.10.2.  Product Offerings

9.10.3.  Financial Performance

9.10.4.  Recent Initiatives

9.11.              JCR Pharmaceuticals Co., Ltd.

9.11.1.  Company Overview

9.11.2.  Product Offerings

9.11.3.  Financial Performance

9.11.4.  Recent Initiatives

9.12.              PHARMICELL Co., Ltd

9.12.1.  Company Overview

9.12.2.  Product Offerings

9.12.3.  Financial Performance

9.12.4.  Recent Initiatives

9.13.              Organogenesis Inc.

9.13.1.  Company Overview

9.13.2.  Product Offerings

9.13.3.  Financial Performance

9.13.4.  Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

Glossary of Terms